Novartis Vijoice first and only treatment for PIK3CA-Related Overgrowth Spectrum

 

• Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 
  
  
• PROS is a spectrum of rare conditions and is characterized by atypical overgrowths and anomalies in blood vessels, the lymphatic system and other tissues2,3  
  
  
• Approval based on real-world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction in the size of PROS lesions and improvement of PROS-related signs and symptoms
  
  
• Novartis to offer robust patient support program that includes assistance to access medication, financial resources for eligible patients and continued education

https://www.globenewswire.com/news-release/2022/04/06/2417163/0/en/FDA-approves-Novartis-Vijoice-alpelisib-as-first-and-only-treatment-for-select-patients-with-PIK3CA-Related-Overgrowth-Spectrum-PROS.html